<DOC>
	<DOCNO>NCT00182793</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . An autologous stem cell transplant may able replace blood-forming cell destroy chemotherapy . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy without trastuzumab follow autologous stem cell transplant radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give combination chemotherapy without trastuzumab follow autologous stem cell transplant radiation therapy work treat patient stage III stage IV breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Trastuzumab Followed By Autologous Stem Cell Transplant Radiation Therapy Treating Patients With Stage III Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility tandem high-dose chemotherapy comprising melphalan , carboplatin , thiotepa , cyclophosphamide without trastuzumab ( Herceptin® ) follow autologous peripheral blood stem cell transplantation helical tomotherapy loco-regional radiotherapy patient high-risk stage IIIB , IIIC , IV breast cancer . - Determine toxic effect regimen patient . OUTLINE : Patients undergo stem cell collection . - Course 1 : Patients receive high-dose melphalan IV without trastuzumab ( Herceptin® ) . One day later , patient undergo autologous peripheral blood stem cell ( PBSC ) transplantation . No 7 week later , patient proceed course 2 . - Course 2 : Patients receive high-dose carboplatin , thiotepa , cyclophosphamide IV continuously 4 day follow autologous PBSC transplantation . After recover high-dose chemotherapy autologous PBSC transplantation , patient stage IIIB IIIC disease undergo radiotherapy chest wall lymph node . Patients stage IV disease undergo radiotherapy use helical tomotherapy standard radiotherapy oligometastatic site . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer , meet 1 follow stage criterion : Stage IIIB IIIC disease , meet follow criterion : Must receive prior neoadjuvant adjuvant therapy Must undergone lumpectomy mastectomy Stage IV disease , meet follow criterion : Only 13 organ site disease involvement induction chemotherapy Achieved least partial response induction chemotherapy No 3 lesion organ site combine Inflammatory breast cancer allow Completed chemotherapy , surgery , radiotherapy breast cancer within past 6 month Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 65 Sex Male female Menopausal status Not specify Performance status Karnofsky 80100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic SGOT SGPT ≤ 2 time upper limit normal Bilirubin ≤ 1.5 mg/dL Renal Creatinine ≤ 1.2 mg/dL Creatinine clearance ≥ 70 mL/min Cardiovascular LVEF ≥ 55 % MUGA echocardiogram Pulmonary FEV_1 ≥ 60 % predict DLCO ≥ 60 % low limit predict value Oxygen saturation &gt; 92 % room air Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No autoimmune disorder No immunosuppressive condition No malignancy within past 5 year PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy except trastuzumab ( Herceptin® ) Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy See Disease Characteristics No prior radiotherapy adjacent involve site disease would preclude study radiotherapy Surgery See Disease Characteristics Other No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>invasive ductal breast carcinoma predominant intraductal component</keyword>
	<keyword>invasive ductal breast carcinoma</keyword>
	<keyword>medullary ductal breast carcinoma lymphocytic infiltrate</keyword>
	<keyword>mucinous ductal breast carcinoma</keyword>
	<keyword>Paget disease breast invasive ductal carcinoma</keyword>
	<keyword>papillary ductal breast carcinoma</keyword>
	<keyword>tubular ductal breast carcinoma</keyword>
	<keyword>invasive lobular breast carcinoma predominant situ component</keyword>
	<keyword>invasive lobular breast carcinoma</keyword>
	<keyword>comedo ductal breast carcinoma</keyword>
</DOC>